BBC & Cytiva agree to work together to support the start-up ecosystem and academia in the field on biopharmaceuticals
Bangalore Bioinnovation Centre (BBC), a bio-incubation Centre for startups set up under the aegis of KITS (Karnataka Innovation Technology Society), Department of Electronics, IT, BT and S&T, Government of Karnataka and Cytiva agree to work together to support the start-up ecosystem and academia in the field on biopharmaceuticals by providing a platform for skill development and industry oriented training in the field of bioprocessing (upstream, downstream and analytical characterisation).
As per the Invest India’s survey, Indian biotechnology industry estimated to reach 150 billion dollars by 2025, expects to see the number of startups to grow from above 4000 to 10,000 by 2025. The Bangalore Bioinnovation Centre is a world class incubation Centre with Central Instrumentation facility in a 10-acre campus with total build up area of 60,000 square feet and is engaged in providing infrastructure support, skill development and assistance to start-up companies, ventures, and projects in biopharmaceutical field to help conversion of innovative ideas and research into commercialization. This collaboration aligns well in giving impetus to the innovation ecosystem by driving industry academia linkages and eventually, enhanced research.
Dr Jitendra, Managing Director, Bangalore Bioinnovation Centre says, “This partnership will help to create a training program catering to the Biopharma Industry which is much needed today”.
Vaggu Raghavendra Goud, General Manager, Cytiva South Asia says, “Cytiva has been supporting the Indian biotechnology industry for more than 30 years. With the industry experiencing fast growth, the need of skilled talents is increasing. This collaboration enables us to bring our global knowledge and expertise to support BBC, local biotech companies and academia in fulfilling the need for skilled talent which will lead to improved efficiency, reduced time and cost of regional biopharma industry development.”
Talent is critical for all industries, but it is particularly critical for the biopharma industry given the complexity of the sector. According to Cytiva Biopharma Resilience Index, talent pool is the weakest link in the global biopharma industry. 65 per cent of Indian respondents in the Biopharma Resilience Index say that sourcing talent in technology, manufacturing, and R&D is a substantial challenge. Thus, the demand for the collaboration is expected to be high.
- Advertisement -